卵巢上皮性癌中mTOR信号通路蛋白的表达及其临床意义

Expression of mTOR signaling pathway protein in ovarian epithelial cancer and its clinical significance

目的:研究哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)信号通路蛋白在人卵巢上皮性癌中的表达及其临床意义。方法:选取武汉同济医院妇产科2005～2008间手术切除并经病理证实的人卵巢上皮性癌63例,其中Ⅰ级12例、Ⅱ级15例、Ⅲ级23例、Ⅳ级13例,应用免疫组织化学法检测卵巢上皮性癌组织中mTOR信号通路关键蛋白pm-TOR、pAKT的表达,分析其与卵巢癌患者临床病理特征的关系。结果:pmTOR在各级卵巢上皮性癌中的阳性率分别为:Ⅰ级41.7%(5/12)、Ⅱ级53.3%(8/15)、Ⅲ级65.2%(15/23)、Ⅳ级69.2%(9/13),pAKT在各级卵巢上皮性癌中的阳性率分别为:Ⅰ级33.3%(5/12)、Ⅱ级40.0%(6/15)、Ⅲ级52.2%(12/23)、Ⅳ级53.8%(7/13);各阳性表达率间无统计学差异(P>0.05),但其表达水平均随着卵巢上皮性癌病理级别的增高而升高,而与病理类型无关。结论:mTOR信号通路蛋白在卵巢上皮性癌的发生发展中起重要的作用,可能是卵巢癌治疗的潜在靶点。

Objective：To study the expression of mammalian target of rapamycin（mTOR） signaling pathway protein in human ovarian epithelial cancer and its clinical significance. Methods：63 cases with ovarian epithelial cancer who underwent resection and were confirmed by pathological examination in the hospital from 2005 to 2008 were selected,including 12 cases of grade Ⅰ,15 cases of grade Ⅱ,23 cases of grade Ⅲ and 13 cases of grade Ⅳ.Immunohistochemical method was used to detect the expression levels of key mTOR signaling pathway proteins（pmTOR and pAKT） in ovarian epithelial cancer tissues,their relationship with clinicopathological characteristics of patients with ovarian cancer was analyzed. Results：The positive rates of pmTOR in ovarian epithelial cancer in different grades were 41.7%（5/12,grade Ⅰ）,53.3%（8/15,grade Ⅱ）,65.2%（15/23,grade Ⅲ） and 69.2%（9/13,grade Ⅳ）,respectively.The positive rates of pAKT in ovarian epithelial cancer in different grades were 33.3%（5/12,grade Ⅰ）,40.0%（6/15,grade Ⅱ）,52.2%（12/23,grade Ⅲ） and 53.8%（7/13,grade Ⅳ）,respectively.There was no significant difference in the positive rates（P0.05）;but the expression levels increased with the increase of pathological grade of ovarian epithelial cancer,it was not correlatd with pathological types. Conclusion：mTOR signaling pathway proteins play important roles in the occurrence and development of ovarian epithelial cancer,and they may serve as potential targets in treatment of ovarian epithelial cancer.